JianqingLinMD

PubMed

• Prostein expression on circulating tumor cells as a prognostic marker in metastatic castration-resistant prostate cancer.
  Zhenchao Zhang, Rui Luo, William K Kelly, Joshua Chen, Shane Donahue
  Prostate Cancer and Prostatic Diseases. 2024-06-01
• Management of Localized Prostate Cancer in Men With Human Immunodeficiency Virus: Analysis of a Large Retrospective Cohort.
  Tina Vaziri, Yuan J Rao, Michael Whalen, Jeffrey Bethony, Punam Thakkar
  Clinical Genitourinary Cancer. 2023-10-01
• 8 citations
  Belzutifan (MK-6482): Biology and Clinical Development in Solid Tumors.
  WonSeok W Choi, Julia L Boland, Akshar Kalola, Jianqing Lin
  Current Oncology Reports. 2023-02-01

Journal Articles

• Immune Biomarkers of Treatment Failure for a Patient with Renal Cell Carcinoma on a Phase I Trial of Pembrolizumab plus Radiotherapy  
  Alexander G, Palmer J, Tuluc M, Lin J, D Craig Hooper DC, Lu B, Journal for ImmunoTherapy of Cancer, 1/1/2015
• Change in PSA Velocity Is a Predictor of Overall Survival in Men with Biochemically-recurrent Prostate Cancer Treated with Nonhormonal Agents: Combined Analysis of Fou...  
  Suzman DL, Zhou XC, Zahurak ML, Lin J, Antonarakis ES, Prostate Cancer Prostatic Dis, 1/1/2015
• An Open Label Randomized Phase II Study of Pasireotide with or without Everolimus in Castrate-resistant Chemotherapy-naive Prostate Cancer Patients  
  Lin J, Deng A, Hoffman-Censits J, Gibney G, Hyslop T, Miller B, Kilpatrick D, Jabbour S, Kelly WK, Cancer Treatment Communications, 1/1/2015
• Phase I/II Study of Orteronel (TAK-700), an Oral, Investigational, Nonsteroidal 17,20-lyase Inhibitor, with Docetaxel and Prednisone (DP) In Metastatic Castration-resi...  
  Petrylak DP, Ghandi JG, Clark WK, Heath E, Lin J, Oh WK, Agus DB, Carthon B, Moran S, Kong N, Suri A, Bargfrede M, Liu G, Invest New Drugs, 1/1/2015
• Accelerated Methotrexate, Vinblastine, Doxorubicin and Cisplatin (AMVAC) Is Safe, Effective and Efficient Neoadjuvant Treatment for Muscle Invasive Bladder Cancer: Res...  
  Plimack ER, Hoffman-Censits JH, Viterbo R, Trabulsi EJ, Ross EA, Greenberg RE, Chen DY, Lallas CD, Wong YN, Lin J, Kutikov A, Dotan E, Brennan TA, Palma N, Dulaimi E, ..., J Clin Oncol, 1/20/2014
• A Pilot Phase II Study of Digoxin in Patients with Recurrent Prostate Cancer as Evident by a Rising PSA  
  Lin J, Zhan T, Duffy D, Hoffman-Censits J, Kilpatrick D, Trabulsi EJ, Lallas CD, Chervoneva I, Limentani K, Kennedy B, Kessler S, Gomella L, Antonarakis ES, Carducci M..., Am J Cancer Ther Pharmacol., 1/7/2014
• A Non-comparative Randomized Phase II Study of 2 Doses of ATN-224, a Copper/zinc Superoxide Dismutase Inhibitor, in Patients with Biochemically Recurrent Hormone-naive...  
  Lin J, Zahurak M, Beer TM, Ryan CJ, Wilding G, Mathew P, Morris M, Callahan JA, Gordon G, Reich SD, Carducci MA, Antonarakis ES, Urol Oncol, 1/1/2013
• Pharmacodynamic study of Disulfiram in Men with Non-metastatic Recurrent Prostate Cancer  
  Schweizer M, Lin J, Blackford A, Bardia A, King S, Armstrong SJ, Rudek MA, Yegnasubramanian S, Carducci MA, Prostate Cancer and Prostatic Diseases, 1/1/2013
• Changes in PSA Kinetics Predict Metastasis-Free Survival in Men with PSA-Recurrent Prostate Cancer Treated with Non-Hormonal Agents: Combined Analysis of 4 Phase II Tr...  
  Antonarakis ES, Zahurak ML, Lin J, Keizman D, Carducci MA, and Eisenberger MA, Cancer, 1/1/2012
• Phase I Trial with a Combination of Docetaxel (Tax) and 153 Sm-EDTMP (Sm) in Patients with Metastatic Castrate Resistant Prostate Cancer (mCRPC) )  
  Lin J, Sinibaldi VJ, Carducci MA, Denmeade S, Song D, DeWeese T, Eisenberger MA, Urologic Oncology, 1/1/2011
• Disulfiram Is a Novel DNMT1 Inhibitor and Inhibits Prostate Cancer Cell Growth  
  Lin J, Haffner MC, Zhang Y, Lee BH, Kachhap S, Nelson WG, Yegnasubramanian S, Carducci MA, Prostate, 1/31/2010
• Downregulation of Homologous Recombination DNA Repair Genes by HDAC Inhibition in Prostate Cancer Cells Is Mediated through Downregulation of the E2F1 Transcription Fa...  
  Kachhap SK, Rosmus N, Collis SJ, Kortenhorst M, Wissing MD, Hedayati M, Shabbeer S, Mendonca J, Deangelis J, Marchionni L, Lin J, Nortier JWR, DeWeese TL, Hammers H an..., Molecular Cancer PLoS One, 1/18/2010
• A Phase I/II Dose Finding Study of 5-Azacytidine in Combination with Sodium Phenybutyrate in Patients with Refractory Solid Tumors  
  Lin J, Gilbert J, Rudek MA, Zweibel JA, Gore S, Jiemijt A, Zaho M, Baker SD, Ambinder RF, Herman JG, Donehower RC, Carducci MA, Clinical Cancer Research, 1/1/2009
• An Oxidative Stress Mechanism Mediates Chelerythrine-induced Heparin-binding EGF-like Growth Factor Ectodomain Shedding  
  Kim J, Lin J, Adam RM, Lamb C, Shively SB, Freeman MR, J Cell Bichem, 1/1/2005
• Transactivation of ErbB1 and ErbB2 Receptors by Angiotensin II in Normal Human Prostate Stromal Cells  
  Lin J. and Freeman MR, Prostate, 1/1/2003
• A Nuclear Form of the Heparin-binding Epidermal Growth Factor-like Growth Factor Precursor Is a Feature of Aggressive Transitional Cell Carcinoma  
  Adam RM, Danciu T, McLellan DL, Borer JG, Lin J, Zurakowski D, Weinstein MH, Rajjayabun PH, Mellon JK, Freeman MR, Cancer Res, 1/1/2003
• Heparin-binding EGF-like Growth Factor Stimulates Androgen-independent Prostate Tumor Growth and Antagonizes Androgen Receptor Function  
  Adam RA, Kim J., Lin J., Orsola A., Zhuang L., Rice DC, and Freeman MR, Endocrinology, 1/1/2002
• Cholesterol-rich Lipid Rafts Mediate Akt-regulated Survival in Prostate Cancer Cells  
  Zhuang L, Lin J, Lu ML, Solomon KR, Freeman MR, Cancer Res, 1/1/2002
• Heparin-binding Epidermal Growth Factor-like Growth Factor Is an Autocrine Mediator of Human Prostate Stromal Cell Growth in Vitro  
  Duque JL, Adam RM, Mullen JS, Lin J, Richie JP, Freeman MR, J Urol., 1/1/2001
• BAG-1 Is a Novel Cytoplasmic Binding Partner of the Membrane Form of Heparin-binding EGF-like Growth Factor, a Unique Role for ProHB-EGF in Cell Survival Regulation  
  Lin J., Hutchinson L., Gaston SM., Raab G., and Freeman MR, J Biol Chem, 1/1/2001
• Heparin-binding EGF-like Growth Factor Is Up- Regulated in the Obstructed Kidney in a Cell- and Region-specific Manner and Acts to Inhibit Apoptosis  
  Nguyen HT, Bride SH, Badawy AB, Adam RM, Lin J, Orsola A, Guthrie PD, Freeman MR, and Peters CA, Am J Pathol, 1/1/2000
• The Phosphatidylinositol 3'-kinase Pathway Is a Dominant Growth Factor-activated Cell Survival Pathway in LNCaP Human Prostate Carcinoma Cells  
  Lin J., Adam R., and Freeman M, Cancer Res, 1/1/1999
• An EGFR Antisense Oligodeoxynucleotides and Its Phosphorothioate Analogues Inhibit the Growth of Human Hepatocarcinoma BEL-7404 Cells  
  Lin JQ, Xu ZS., Zhang HY., Yang ZH., and Xu YH, Shih-Yen-Sheng-Wu-Hsueh-Pao, 1/1/1995
• A Study of Effects and Mechanism of Retinoic Acid on Inducing Differentiation of Mouse Lymphoma SACIIB2 Clone Cells  
  Lin J, Kong X and Cheng L, Acta Academiae Medicinae Shanghai, 1/1/1994
• Retinoic Acid Induces Differentiation of Human T Lymphocytic Leukemia CCRF-CEM Cells  
  Lin JQ, Zhonghua Zhong Liu Za Zhi., 1/1/1993
• Join now to see all

Abstracts/Posters

• A phase I/II study of the investigational drug alisertib in combination with abiraterone and prednisone (AP) for patients with metastatic castration-resistant prostate...
  Jianqing Lin, Ashwin R. Sama, Jean. H. Hoffman-Censits, Brooke Kennedy, Debraoh Kilpatrick, Ye Zhong, Hushan Yang, Zhaomei Mu, Benjamin E. Leiby, Nancy Lewis, Massimo ..., 2016 GU ASCO Symposium, 2016